Is Privia Health Group (PRVA) overvalued or fairly valued?

MarketChacha shows Privia Health Group's valuation in context — a trailing P/E of about 143.3, a forward P/E of about 21.7, a price-to-book of about 3.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Privia Health Group's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (5.85×) from reported figures — education, not a rating.

What is Privia Health Group's revenue?

Privia Health Group reported revenue of $2.1B for FY2025, with net profit of $22.9M, per official filings.

What is the share price of Privia Health Group (PRVA)?

Privia Health Group last traded at $22.93 (+2.2% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Privia Health Group

PRVA · NYSE · Healthcare · United States

Snapshot

TickerPRVA

ExchangeNYSE

SectorHealthcare

IndustryHealth Information Services

CountryUnited States

Employees1,226

HeadquartersArlington, United States

Websitewww.priviahealth.com

Filings tracked17

About Privia Health Group

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.

Who owns it

Insiders6.2%
Institutions93.8%
Public & other0.0%

402 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.76%
FMR, LLC10.06%
Durable Capital Partners Lp9.11%
Vanguard Portfolio Management LLC5.15%
Rubicon Founders LLC4.67%
Vanguard Capital Management LLC4.04%
State Street Corporation3.84%
Van Berkom & Associates Inc.2.91%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 3.1% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion5.85×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend1.4% → 1.1%

Margin has held broadly steady over the period — stable profitability.

Return on equity3.1%

Latest ROE of 3.1% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 13% · PAT -0%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $611.3M · EPS 0.25

Est. earnings growth -1.6%

Next fiscal year

Rev $2.7B · EPS 1.06

Est. earnings growth +19.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.1B

Net margin

1.1%

ROE

3.1%

Revenue CAGR (2y)

+13.2%

Profit CAGR (2y)

-0.3%

EPS (FY2025)

0.18

Net profit (FY2025)

$22.9M

Ask MarketChacha about PRVA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.1B	$22.9M	0.18	1.1%	3.1%
FY2024	$1.7B	$14.4M	0.11	0.8%	2.3%
FY2023	$1.7B	$23.1M	0.19	1.4%	4.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$632.6M	$9.0M	0.07	1.4%
2026Q1	$603.8M	$3.1M	0.02	0.5%
2025Q3	$580.4M	$6.9M	0.05	1.2%
2025Q2	$521.2M	$2.7M	0.02	0.5%
2025Q1	$480.1M	$4.2M	0.03	0.9%
2024Q3	$437.9M	$3.5M	0.03	0.8%
2024Q2	$422.3M	$3.5M	0.03	0.8%
2024Q1	$415.2M	$3.0M	0.02	0.7%
2023Q3	$417.3M	$5.6M	0.05	1.4%
2023Q2	$413.4M	$7.3M	0.06	1.8%
2023Q1	$386.3M	$7.3M	0.06	1.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC8/18/2026material
8-K — Results of operations, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Executive/director change
SEC7/7/2026material
8-K — Shareholder vote results
SEC5/22/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
10-K filing
SEC2/27/2026
8-K — Results of operations, Exhibits
SEC2/26/2026material

2025

8-K — Other events
SEC12/8/2025material
8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Other events
SEC10/28/2025material
8-K — Other events
SEC9/23/2025material
8-K — Reg FD disclosure, Exhibits
SEC8/29/2025material
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.